Silence Therapeutics plc (NASDAQ:SLN) Receives $40.67 Average Target Price from Brokerages

Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $40.67.

A number of brokerages recently commented on SLN. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a research report on Friday, March 7th. Chardan Capital reiterated a "buy" rating and issued a $55.00 target price on shares of Silence Therapeutics in a research note on Tuesday, December 10th. BMO Capital Markets decreased their price target on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday, March 4th. Morgan Stanley dropped their price objective on Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. Finally, The Goldman Sachs Group decreased their target price on Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating for the company in a research report on Tuesday, March 4th.

Silence Therapeutics Stock Up 2.1 %

SLN stock traded up $0.08 during trading on Monday, reaching $3.57. The stock had a trading volume of 179,216 shares, compared to its average volume of 276,633. Silence Therapeutics has a one year low of $3.41 and a one year high of $24.38. The company's 50 day moving average is $4.78 and its two-hundred day moving average is $10.22. The company has a market capitalization of $106.70 million, a price-to-earnings ratio of -2.26 and a beta of 1.08.

Remove Ads

Institutional Investors Weigh In On Silence Therapeutics

Several institutional investors have recently made changes to their positions in SLN. JPMorgan Chase & Co. purchased a new stake in Silence Therapeutics during the 4th quarter worth about $26,000. GAMMA Investing LLC increased its position in shares of Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock valued at $42,000 after buying an additional 5,233 shares during the period. Barclays PLC lifted its holdings in shares of Silence Therapeutics by 83.8% in the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock worth $42,000 after buying an additional 2,793 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Silence Therapeutics in the fourth quarter valued at approximately $69,000. Finally, Virtus ETF Advisers LLC grew its stake in Silence Therapeutics by 130.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock valued at $74,000 after acquiring an additional 6,098 shares in the last quarter. Hedge funds and other institutional investors own 98.73% of the company's stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.